US Patent

US8771733 — Pharmaceutical composition containing an anti-nucleating agent

Method of Use · Assigned to Merck Sharp and Dohme LLC · Expires 2030-06-02 · 4y remaining

Vulnerability score 76/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a pharmaceutical composition containing an anti-nucleating agent suitable for oral administration in solid dosage forms.

USPTO Abstract

Pharmaceutical compositions suitable for oral administration in solid dosage forms are described. The compositions comprise an effective amount of a drug compound in the form of a salt, wherein the drug salt is characterized by conversion to a less soluble form of the drug compound under certain pH conditions, and an anti-nucleating agent.

Drugs covered by this patent

raltegravir-potassium (RALTEGRAVIR POTASSIUM)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-257`	—	raltegravir-potassium
`U-257`	—	raltegravir-potassium
`U-257`	—	raltegravir-potassium

Patent Metadata

Patent number: US8771733
Jurisdiction: US
Classification: Method of Use
Expires: 2030-06-02
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Merck Sharp and Dohme LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.